Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis.
Consuegra-Fernández M, Julià M, Martínez-Florensa M, Aranda F, Català C, Armiger-Borràs N, Arias MT, Santiago F, Guilabert A, Esteve A, Muñoz C, Ferrándiz C, Carrascosa JM, Pedrosa E, Romaní J, Alsina M, Mascaró-Galy JM, Lozano F. Consuegra-Fernández M, et al. Among authors: esteve a. Cell Mol Immunol. 2018 Oct;15(10):898-906. doi: 10.1038/cmi.2017.119. Epub 2017 Dec 11. Cell Mol Immunol. 2018. PMID: 29225340 Free PMC article.
Genetically defined variants of toll-like receptors 3, 7 and 9 as phenotype and risk modifier factors for psoriasis.
Julià M, Consuegra-Fernández M, Guilabert A, Muñoz C, Esteve A, Armiger-Borràs N, Santiago F, Arias MT, Romaní J, Ferrándiz C, Carrascosa JM, Pedrosa E, Alsina-Gibert M, Lozano F, Mascaró-Galy JM. Julià M, et al. Among authors: esteve a. J Dermatol Sci. 2018 Mar;89(3):301-304. doi: 10.1016/j.jdermsci.2017.12.004. Epub 2017 Dec 19. J Dermatol Sci. 2018. PMID: 29290528 No abstract available.
Corrigendum to "Genetically defined variants of toll-like receptors 3, 7 and 9 as phenotype and risk modifier factors for psoriasis" [89 (March (3)) (2018) 301-304].
Julià M, Consuegra-Fernández M, Guilabert A, Muñoz C, Esteve A, Armiger-Borràs N, Santiago F, Arias MT, Romaní J, Ferrándiz C, Carrascosa JM, Pedrosa E, Alsina-Gibert M, Lozano F, Mascaró-Galy JM. Julià M, et al. Among authors: esteve a. J Dermatol Sci. 2018 Sep;91(3):342. doi: 10.1016/j.jdermsci.2018.03.013. Epub 2018 Apr 1. J Dermatol Sci. 2018. PMID: 29615327 No abstract available.
CCL4L polymorphisms and CCL4/CCL4L serum levels are associated with psoriasis severity.
Pedrosa E, Carretero-Iglesia L, Boada A, Colobran R, Faner R, Pujol-Autonell I, Palou E, Esteve A, Pujol-Borrell R, Ferrándiz C, Juan M, Carrascosa JM. Pedrosa E, et al. Among authors: esteve a. J Invest Dermatol. 2011 Sep;131(9):1830-7. doi: 10.1038/jid.2011.127. Epub 2011 May 26. J Invest Dermatol. 2011. PMID: 21614014 Free article.
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
HIV-CAUSAL Collaboration; Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA. HIV-CAUSAL Collaboration, et al. Among authors: esteve a. Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6. Clin Infect Dis. 2015. PMID: 25567330 Free PMC article.
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.
HIV-CAUSAL Collaboration; Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA. HIV-CAUSAL Collaboration, et al. Among authors: esteve a. Ann Intern Med. 2011 Apr 19;154(8):509-15. doi: 10.7326/0003-4819-154-8-201104190-00001. Ann Intern Med. 2011. PMID: 21502648 Free PMC article.
Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort.
Manzardo C, Esteve A, Ortega N, Podzamczer D, Murillas J, Segura F, Force L, Tural C, Vilaró J, Masabeu A, Garcia I, Guadarrama M, Ferrer E, Riera M, Navarro G, Clotet B, Gatell JM, Casabona J, Miró JM; PISCIS Investigators. Manzardo C, et al. Among authors: esteve a. Clin Microbiol Infect. 2013 Jul;19(7):646-53. doi: 10.1111/j.1469-0691.2012.03991.x. Epub 2012 Sep 12. Clin Microbiol Infect. 2013. PMID: 22967234 Free article.
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.
HIV-CAUSAL Collaboration; Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casbona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, García de Olalla P, Hernán MA. HIV-CAUSAL Collaboration, et al. Among authors: esteve a. AIDS. 2010 Jan 2;24(1):123-37. doi: 10.1097/QAD.0b013e3283324283. AIDS. 2010. PMID: 19770621 Free PMC article.
[Fungemia in patients with HIV infection].
Santos J, Palacios R, Esteve A, García V, Rivero A, Márquez M. Santos J, et al. Among authors: esteve a. An Med Interna. 1998 Oct;15(10):523-7. An Med Interna. 1998. PMID: 9844226 Spanish.
249 results